264 completed, 127 recruiting, 117 active not recruiting, 94 unknown. 720 Phase 3, 70 Phase 2.
Follow Carboplatin: new trials by email Literature Review of Carboplatin trials Research Report on Carboplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer | Phase 3 | Not yet recruiting | Asan Medical Center | 172 | 2026-12-31 | 2026-10-29 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 166 | 2026-11-01 | 2026-10-28 |
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC ASKC202, ASKC202 placebo, osimertinib placebo - EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 425 | 2026-10-30 | 2026-10-27 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-27 | 2026-10-30 |
| HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer | Phase 3 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 333 | 2026-10-20 | 2026-10-29 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-30 |
| A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed - NSCLC | Phase 3 | Not yet recruiting | Shanghai Jeyou Pharmaceutical Co., Ltd. | 416 | 2026-10-01 | 2026-09-24 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection, Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection - Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 540 | 2026-09-30 | 2026-09-22 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 940 | 2026-09-22 | 2026-10-20 |
| Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 206 | 2026-09-17 | 2026-08-10 |
| Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Bristol-Myers Squibb | 850 | 2026-09-08 | 2026-10-26 |
Showing 20 of 720. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (216) · Lung Neoplasms (73) · Ovarian Neoplasms (70) · Breast Neoplasms (44) · Fallopian Tube Neoplasms (36) · Small Cell Lung Carcinoma (35) · Triple Negative Breast Neoplasms (29) · Parkinson Disease 4, Autosomal Dominant Lewy Body (28) · Carcinoma, Ovarian Epithelial (27) · Uterine Cervical Neoplasms (25) · Squamous Cell Carcinoma of Head and Neck (20) · Adenocarcinoma of Lung (18) · Endometrial Neoplasms (18) · Neuroblastoma (18) · Carcinoma (17)
Merck Sharp & Dohme LLC (42) · National Cancer Institute (NCI) (35) · AstraZeneca (33) · Hoffmann-La Roche (29) · Children's Oncology Group (23) · Bristol-Myers Squibb (22) · Eli Lilly and Company (11) · AbbVie (9) · Alliance for Clinical Trials in Oncology (8) · Fudan University (8) · SWOG Cancer Research Network (8) · Shanghai Henlius Biotech (8) · Sun Yat-sen University (8) · Akeso (7) · Jiangsu HengRui Medicine Co., Ltd. (7)
United States (329) · China (272) · Spain (190) · Germany (186) · Italy (183) · Canada (179) · United Kingdom (176) · France (175) · South Korea (164) · Australia (155) · Japan (150) · Poland (145) · Taiwan (136) · Belgium (131) · Brazil (129)
Francesco Perrone, M.D., Ph.D. (3)
PMID 37185961, PMID 35511917, PMID 37465924, PMID 38431043, PMID 38642841, PMID 21941283, PMID 33358660, PMID 36795388, PMID 37419867, PMID 40966692, PMID 20567002, PMID 22547591, PMID 30002437, PMID 32450725, PMID 33231285, PMID 33395032, PMID 33538338, PMID 33684371, PMID 35073727, PMID 36793385, PMID 37158938, PMID 37407274, PMID 37411031, PMID 37699333, PMID 37922432, PMID 38383458, PMID 38468440, PMID 39230120, PMID 39369790, PMID 40311309, PMID 40498298, PMID 40932107, PMID 41332393, PMID 41747891, PMID 42579028, PMID 10481771, PMID 10655437, PMID 11165136, PMID 11304695, PMID 11464889, PMID 11479630, PMID 11917283, PMID 12101494, PMID 12697884, PMID 12826431, PMID 12860964, PMID 12932669, PMID 14656276, PMID 14731343, PMID 15001263
2023 (32), U10CA180868 (27), 2014 (17), 2016 (16), U10CA180886 (14), 2018 (13), 2015 (12), 2019 (12), 2025 (12), U10CA027469 (12), U10CA098543 (12), U10CA180820 (12), 2017 (10), U10CA031946 (5), U10CA032102 (5)